Ignite Creation Date:
2025-12-24 @ 6:59 PM
Ignite Modification Date:
2026-01-04 @ 7:50 AM
Study NCT ID:
NCT00367757
Status:
COMPLETED
Last Update Posted:
2019-01-30
First Post:
2006-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial
Sponsor:
Abbott Medical Devices
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Atrial Fibrillation | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | paroxysmal atrial fibrillation | View |
| None | persistent atrial fibrillation | View |
| None | high burden of atrial fibrillation | View |
| None | atrial fibrillation ablation | View |
| None | Pulmonary vein isolation | View |
| None | AF trigger | View |
| None | complex fractionated electrograms | View |
| None | CFE | View |
| None | CFAE | View |
| None | complex fractionated atrial electrograms | View |
| None | refractory antiarrhythmic medication | View |
| None | PVAI | View |
| None | Ensite NavX | View |
| None | NavX | View |
| None | CoolPath catheter | View |
| None | irrigated ablation catheter | View |
| None | high burden of paroxysmal or persistent atrial fibrillation | View |
| None | candidates for AF ablation | View |
| None | symptomatic AF | View |
| None | AF is refractory to at least one antiarrhythmic medication | View |